Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2025-10-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 334.3KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report for the period ending 30 September 2025' and includes detailed operational updates, R&D progress, regulatory milestones, and an Appendix 4C Quarterly Cash Flow Report. The Appendix 4C is a standard Australian Securities Exchange (ASX) quarterly cash flow report, which contains actual financial data for the quarter. The document length is substantial (15,000 characters), and it contains substantive financial data and analysis for a period shorter than a full fiscal year (quarterly). This matches the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a brief summary, nor is it a full annual report or earnings release. Therefore, the correct classification is IR with high confidence. Q1 2026
2025-10-27 English
Notice of Annual General Meeting/Proxy Form 22 pages 502.3KB
AGM Information Classification · 100% confidence The document is a detailed notice and proxy form for an Annual General Meeting (AGM) of Neurotech International Limited. It includes the date and location of the meeting, instructions for voting, the agenda including resolutions to be voted on, and explanatory statements related to the AGM business such as adoption of the remuneration report, re-election of directors, and approval of share issuance mandates. It explicitly states it is a "Notice of Annual General Meeting" and contains no financial statements or detailed financial data itself, but rather instructions and information for shareholders to participate in the AGM. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including notices and proxy forms. The document is not an Annual Report (10-K) or Remuneration Information (DEF 14A) because it does not contain the actual reports, only references and resolutions related to them. It is also not a Declaration of Voting Results (DVA) as it precedes the meeting and voting. Therefore, the correct classification is AGM Information (AGM-R).
2025-10-19 English
Annual Report (Typeset) 31 pages 5.4MB
Annual Report Classification · 100% confidence The document is titled '2025 Annual Report' and contains detailed sections typical of an annual report, including a Chairman's Letter, Directors' Report, financial statements, auditor's report, and comprehensive operational and clinical trial updates for the fiscal year ended 30 June 2025. It includes detailed financial results, director information, auditor details, and extensive narrative on company activities and clinical progress, all consistent with a full annual report. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is the full report, not just an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2025-10-15 English
US FDA Rare Pediatric Disease Designation in Rett syndrome 2 pages 255.1KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 8 October 2025 regarding the US FDA granting Rare Pediatric Disease Designation for the company's drug candidate NTI164 in Rett syndrome. It highlights regulatory milestones, benefits of the designation, and company background. There are no financial statements, earnings data, or detailed financial analysis. The document is a regulatory update about a milestone in drug development and regulatory status, not a financial report or detailed investor presentation. It is not a report publication announcement since it contains substantive content about the designation. The best fitting category is Capital/Financing Update (CAP) as it relates to regulatory milestones that impact the company's financing and market position, or alternatively Regulatory Filings (RNS) as a general regulatory announcement. Given the focus on regulatory milestone and market exclusivity benefits, CAP is more appropriate with high confidence.
2025-10-07 English
Neurotech initiates NTI164 Authorised Prescriber Program 2 pages 220.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 23 September 2025 from Neurotech International Limited. It announces the initiation of an Authorised Prescriber (AP) program for their therapy NTI164, providing controlled access to the drug for eligible patients in Australia. The content focuses on the program's objectives, management, pricing, and strategic positioning within regulatory and commercial frameworks. There are no financial statements, quarterly or annual results, nor is this a transcript, audit, or legal proceeding. The document is a corporate announcement about a new program and its strategic implications, not a financial report or regulatory filing of a financial nature. It is not a report publication announcement since it does not mention the release or availability of a report. Therefore, the best fitting category is a Regulatory Filing (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other specific categories.
2025-09-22 English
Release of Shares from Voluntary Escrow 1 page 86.1
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement dated 5 September 2025 regarding the release of 10,000,000 shares from voluntary escrow. It references compliance with Listing Rule 3.10A and details the lifting of holding locks on shares. The content is a brief announcement about share escrow release and does not contain financial statements, management discussion, or detailed financial data. The document length is short (2438 characters) and it is clearly an announcement of a capital-related event (release of shares from escrow). This fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding share issues, stock splits, or other capital changes such as escrow releases.
2025-09-04 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.